No abstract

Background The representation of sociodemographic data within randomized-controlled trials (RCT) regarding foot and ankle surgery is undefined. The purpose of this study was to determine the incidence of sociodemographic data being reported in contemporary foot and ankle RCTs. Methods Randomized-controlled trials within the PubMed database from 2016 to 2021 were searched and the full text of 40 articles was reviewed to identify sociodemographic variables reported in the manuscript. Data regarding race, ethnicity, insurance status, income, work status, and education were collected. Results Race was reported in the results in 4 studies (10.0%), ethnicity in 1 (2.5%), insurance status in 0 (0%), income in 1 (2.5%), work status in 3 (7.5%) and education in 2 (5.0%). In any section other than the results, race was reported in 6 studies (15.0%), ethnicity in 1 (2.5%), insurance status in 3 (7.5%), income in 6 (15.0%), work status in 6 (15.0%), and education in 3 (7.5%). There was no difference in sociodemographic data by journal (P = .212), year of publication (P = .216), or outcome study (P = .604). Conclusion The overall rate of sociodemographic data reported in foot and ankle RCTs is low. There was no difference in the reporting of sociodemographic data between journal, year of publication, or outcome study. Level of Evidence: Level II

Prosthetic joint infection (PJI) is a costly and potentially fatal complication in total ankle arthroplasty (TAA). Some surgeons apply topical vancomycin powder to minimize the risk of infection during TAA procedures. The purpose of our study was to determine the cost-effectiveness of using vancomycin powder to prevent PJI following TAA and to propose an economic model that can be applied by foot and ankle surgeons in their decision to incorporate vancomycin powder in practice. Using our institution’s records of the cost of 1 g of topical vancomycin powder, we performed a break-even analysis and calculated the absolute risk reduction and number needed to treat for varying costs of vancomycin powder, PJI infection rates, and costs of TAA revision. Costing $3.06 per gram at our institution, vancomycin powder was determined to be cost-effective in TAA if the PJI rate of 3% decreased by an absolute risk reduction of 0.02% (Number Needed to Treat = 5304). Furthermore, our results indicate that vancomycin powder can be highly cost-effective across a wide range of costs, PJI infection rates, and varying costs of TAA revision. The use of vancomycin powder remained cost-effective even when (1) the price of vancomycin powder was as low as $2.50 to as high as $100.00, (2) infection rates ranged from .05 to 3%, and (3) the cost of the TAA revision procedure ranged from $1000 to $10 000. Levels of Evidence: IV

OBJECTIVE:The opioid crisis has drawn widespread professional and media attention, yet the extent to which this crisis has changed prescribing practices is unknown. We aimed to assess temporal trends in postpartum (PP) opioid prescribing, opioid use, and pain control satisfaction. STUDY DESIGN: This was a secondary analysis of a prospective observational study of opioid-naïve PP women who delivered at a large tertiary care center (5/2017-7/2019) and used an opioid during their PP hospitalization. Enrolled women completed surveys regarding their PP pain control. The amount of opioids used during inpatient hospitalization (morphine milligram equivalents [MME] / hospital day) and prescribed at discharge were obtained from medical records. The primary outcome was the difference over time in opioid prescribing at discharge, measured by the proportion who received and total MME of prescriptions at discharge. Additional outcomes were opioid use (assessed by total inpatient MME/day and self-reported amount of opioid used after discharge) and satisfaction with PP pain control. Trends over time were evaluated using non-parametric tests of trend. RESULTS: Of 2,470 women screened for eligibility, a majority (N¼1,488; 60.2%) did not use an opioid during their PP inpatient hospitalization. Over the study period, there was a significant decline in the proportion of screened women who used any opioid while inpatient ( Figure A; p< 0.001). Of the 900 women who were screened and used inpatient opioids, 54.3% (N¼471) consented to be followed after discharge. Among these women, there was a significant decline in opioid use in MME/inpatient day (p< 0.001), as well as in both the proportion of women who received an opioid prescription upon discharge ( Figure B; p< 0.001) and the total MME prescribed at discharge (p< 0.001). Both inpatient and outpatient satisfaction with pain control were unchanged (Table). CONCLUSION: In this population, both the frequency and amount of opioid use in the PP period declined from 2017 to 2019, without any change in satisfaction with pain control. ajog.orgPoster Session I